Similar to a patient with colon cancer [21, 45, 50], the stimulation with TKD/IL-2 induced a shift towards the CD3−/CD56bright NK cell subset which was further propagated by nivolumab. This evidence concerns the gene IL2 and malignant colon neoplasm.